Citations

Institution: Mayo Clinic Clear

Showing 10 of 108162 citations.

Incidence and 1‐Year Outcomes of Perioperative Atrial Arrhythmia in Elderly Adults After Hip Fracture Surgery
Gupta, Bhanu , Steckelberg, Rachel C. , Gullerud, Rachel E., Huddleston, P.M. , Kirkland, Lisa L., Wright, R. Scott , Huddleston, Jeanne M. , Huddleston, Paul M, Huddleston, Paul M

Journal of the American Geriatrics Society | October 27, 2015 | Volume: 63 | Issue: 11 | Pages: 2269-2274

10.1111/jgs.13789 | PMID 26503010 Get It

Objectives To determine the incidence and 1‐year outcomes of an elderly population with perioperative atrial arrhythmia (PAA) within 7 days of hip fracture surgery. Design Retrospective cohort study. Setting The Rochester Epidemiology Project (REP). Participants Elderly adults consecutive undergoing hip fracture repair from 1988 to 2002 in Olmsted County, Minnesota (N = 1,088, mean age 84.0 ± 7.4, 80.2% female). Measurements Baseline clinical variables were analyzed in relation to survival using Cox proportional hazards methods for comparison. Results Sixty‐one participants (5.6%) developed PAA within the first 7 days. During 1 year of follow‐up, 239 (22%) participants died. PAA was associated with greater mortality (45% vs 21%; hazard ratio (HR) = 2.8, 95% confidence interval (CI) = 1.9–4.2). Other mortality risk factors were male sex (HR = 2.0, 95% CI = 1.5–2.6), congestive heart failure (HR = 2.1, 95% CI = 1.7–2.8), chronic renal insufficiency (HR = 2.0, 95% CI = 1.5–2.8), dementia (HR = 2.9, 95% CI = 2.2–3.7), and American Society of Anesthesiologists risk Class III, IV, or V (HR = 3.3, 95% CI = 1.9–5.9). Conclusion Elderly adults undergoing hip fracture surgery who develop PAA within 7 days have significantly higher 1‐year mortality than those who do not. Further studies are indicated to determine whether prevention of PAA will reduce mortality in this population.
Challenges in the Pharmacological Management of Nursing Home Residents with Overactive Bladder or Urinary Incontinence
Allen, Carrie D. , O’Shea, Terrence, Tangalos, Eric G., Berner, Todd , Ouslander, Joseph G. , Zarowitz, Barbara J.M.

Journal of the American Geriatrics Society | October 27, 2015 | Volume: 63 | Issue: 11 | Pages: 2298-2307

10.1111/jgs.13713 | PMID 26503458 Get It

Objectives To determine the proportion of nursing home ( NH ) residents ( NHR ) with overactive bladder ( OAB ) or urinary incontinence ( UI ) with potential pharmacodynamic contraindications to antimuscarinic treatment because of concomitant anticholinergic medications or acetylcholinesterase inhibitors ( AC h EI s) and nonpharmacological limitations to antimuscarinic treatment. Design Cross‐sectional retrospective analysis. Setting U.S. skilled nursing facilities. Participants Nursing home residents with a diagnosis of OAB or UI . Measurements Linked and deidentified pharmacy claims and Minimum Data Set ( MDS ) 3.0 records (October 1, 2010 to September 30, 2012). Results Of NHR s, 71.3% received at least one anticholinergic medication. Medications that can cause or worsen UI were used commonly. AC h EI s and antimuscarinic treatment were prescribed concurrently in 24% of NHR s with OAB or UI . NHR s with OAB or UI were more likely to have concurrent moderate to severe cognitive impairment ( MSCI ) (70.1%) than those without (29.9%) ( P < .001). NHR s with or without OAB or UI and with MSCI were more likely to be treated with an anticholinergic medication than those without MSCI ( P = .001). When NHR s with MSCI , severe mobility impairment ( SMI ), and anticholinergic medication and AC h EI use were excluded, only a small proportion of NHR s were potential candidates for antimuscarinic treatment (6.6% with OAB or UI , 6.2% with UI ). Conclusions This study advances understanding of the challenges in prescribing antimuscarinic treatment safely and appropriately in elderly NHR s with a high prevalence of drug interactions, underlying MSCI , and SMI .
Clinical Utility of Metrics Based on Tumor Measurements in Phase II Trials to Predict Overall Survival Outcomes in Phase III Trials by Using Resampling Methods
An, Ming‐Wen , Han, Yunah , Meyers, Jeffrey P., Bogaerts, Jan , Mandrekar, Sumithra J. , Sargent, Daniel J.

Journal of Clinical Oncology | October 27, 2015 | Volume: 33 | Issue: 34 | Pages: 4048-4057

10.1200/jco.2015.60.8778 | PMID 26503199 Get It

Purpose Phase II clinical trials inform go/no-go decisions for proceeding to phase III trials, and appropriate end points in phase II trials are critical for facilitating this decision. Phase II solid tumor trials have traditionally used end points such as tumor response defined by Response Evaluation Criteria for Solid Tumors (RECIST). We previously reported that absolute and relative changes in tumor measurements demonstrated potential, but not convincing, improvement over RECIST to predict overall survival (OS). We have evaluated the metrics by using additional measures of clinical utility and data from phase III trials. Methods Resampling methods were used to assess the clinical utility of metrics to predict phase III outcomes from simulated phase II trials. In all, 2,000 phase II trials were simulated from four actual phase III trials (two positive for OS and two negative for OS). Cox models for three metrics landmarked at 12 weeks and adjusted for baseline tumor burden were fit for each phase II trial: absolute changes, relative changes, and RECIST. Clinical utility was assessed by positive predictive value and negative predictive value, that is, the probability of a positive or negative phase II trial predicting an effective or ineffective phase III conclusion, by prediction error, and by concordance index (c-index). Results Absolute and relative change metrics had higher positive predictive value and negative predictive value than RECIST in five of six treatment comparisons and lower prediction error curves in all six. However, differences were negligible. No statistically significant difference in c-index across metrics was found. Conclusion The absolute and relative change metrics are not meaningfully better than RECIST in predicting OS.
Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group
Weigel, Brenda J. , Lyden, Elizabeth , Anderson, James R. , Meyer, William H. , Parham, David M. , Rodeberg, David A. , Michalski, Jeff M. , Hawkins, Douglas S. , Arndt, Carola A.S., Hawkins, Douglas S

Journal of Clinical Oncology | October 26, 2015 | Volume: 34 | Issue: 2 | Pages: 117-122

10.1200/jco.2015.63.4048 | PMID 26503200 Get It

Purpose Patients with metastatic rhabdomyosarcoma (RMS), except those younger than 10 years with embryonal RMS, have an estimated long-term event-free survival (EFS) of less than 20%. The main goal of this study was to improve outcome of patients with metastatic RMS by dose intensification with interval compression, use of the most active agents determined in phase II window studies, and use of irinotecan as a radiation sensitizer. Patients and Methods Patients with metastatic RMS received 54 weeks of therapy: blocks of therapy with vincristine/irinotecan (weeks 1 to 6, 20 to 25, and 47 to 52), interval compression with vincristine/doxorubicin/cyclophosphamide alternating with etoposide/ifosfamide (weeks 7 to 19 and 26 to 34), and vincristine/dactinomycin/cyclophosphamide (weeks 38 to 46). Radiation therapy occurred at weeks 20 to 25 (primary) but was also permitted at weeks 1 to 6 (for intracranial or paraspinal extension) and weeks 47 to 52 (for extensive metastatic sites). Results One hundred nine eligible patients were enrolled, with a median follow-up of surviving patients of 3.8 years (3-year EFS for all patients, 38% [95% CI, 29% to 48%]; survival, 56% [95% CI, 46% to 66%]). Patients with one or no Oberlin risk factor (age > 10 years or < 1 year, unfavorable primary site of disease, ≥ three metastatic sites, and bone or bone marrow involvement) had a 3-year EFS of 69% (95% CI, 52% to 82%); high-risk patients with two or more risk factors had a 3-year EFS of 20% (95% CI, 11% to 30%). Toxicity was similar to that on prior RMS studies. Conclusion Patients with metastatic RMS with one or no Oberlin risk factor had an improved 3-year EFS of 69% on ARST0431 compared with an historical cohort from pooled European and US studies; those with two or more risk factors have a dismal prognosis, and new approaches are needed for this very-high-risk group.
Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database
Renfro, Lindsay A. , Loupakis, Fotios , Adams, Richard , Seymour, Michel , Heinemann, Volker , Douillard, Jean‐Yves , Hurwitz, Herbert I. , Fuchs, Charles S. , Díaz‐Rubio, Eduardo , Porschen, Rainer, Tournigand, Christophe , Chibaudel, Benoist , Falcone, Alfredo , Punt, Cornelis J.A. , Hecht, J. Randolph , Bokemeyer, Carsten , Goldberg, Richard M. , Saltz, Leonard B. , Gramont, Aimery de , Lenz, Heinz‐Josef , Adams, Richard A, Seymour, Matthew T, Schmoll, Hans‐Joachim , Hurwitz, Herbert, Díaz-Rubio, Eduardo, Tebbutt, Niall C. , van Cutsem, Eric, de Gramont, Aimery, Cutsem, Eric Van , Sargent, Daniel J. , Saltz, Leonard , Falcone, Alfredo , Seymour, Matthew T , Adams, Richard , Chibaudel, Benoist

Journal of Clinical Oncology | October 26, 2015 | Volume: 34 | Issue: 2 | Pages: 144-150

10.1200/jco.2015.61.6441 | PMID 26503203 Get It

Purpose In recent retrospective analyses of early-stage colorectal cancer (CRC), low and high body mass index (BMI) scores were associated with worsened outcomes. Whether BMI is a prognostic or predictive factor in metastatic CRC (mCRC) is unclear. Patients and Methods Individual data from 21,149 patients enrolled onto 25 first-line mCRC trials during 1997 to 2012 were pooled. We assessed both prognostic and predictive effects of BMI on overall survival and progression-free survival, and we accounted for patient and tumor characteristics and therapy type (targeted v nontargeted). Results BMI was prognostic for overall survival (P < .001) and progression-free survival (P < .001), with an L-shaped pattern. That is, risk of progression and/or death was greatest for low BMI; risk decreased as BMI increased to approximately 28 kg/m 2 , and then it plateaued. Relative to obese patients, patients with a BMI of 18.5 kg/m 2 had a 27% increased risk of having a PFS event (95% CI, 20% to 34%) and a 50% increased risk of death (95% CI, 43% to 56%). Low BMI was associated with poorer survival for men than women (interaction P < .001). BMI was not predictive of treatment effect. Conclusion Low BMI is associated with an increased risk of progression and death among the patients enrolled on the mCRC trials, with no increased risk for elevated BMI, in contrast to the adjuvant setting. Possible explanations include negative effects related to cancer cachexia in patients with low BMI, increased drug delivery or selection bias in patients with high BMI, and potential for an interaction between BMI and molecular signaling pathways.
All‐Inside Posterior Cruciate Ligament Reconstruction: GraftLink Technique
Prince, Matthew, King, Alexander H. , Sousa, Paul L., Levy, Bruce A. , Prince, Matthew R, Stuart, Michael J.

Arthroscopy Techniques | October 26, 2015 | Volume: 4 | Issue: 5 | Pages: No page available

10.1016/j.eats.2015.06.009 | PMID 26900564 Get It

Abstract Posterior cruciate ligament (PCL) injuries account for nearly 20% of knee ligament injuries. PCL injuries can occur in isolation or, more commonly, in the setting of multiligamentous knee injuries. Isolated PCL disruptions are commonly treated nonoperatively; however, symptomatic grade III injuries, as well as PCL injuries found in multiligamentous injuries, are frequently treated surgically. Several reconstructive techniques exist for the treatment of PCL deficiency without a clear optimal approach. We describe our preferred operative technique to reconstruct the PCL using an all‐inside arthroscopic approach with a quadrupled tibialis anterior or peroneus longus allograft with both tibial and femoral suspensory fixation. Technique Video video See video under supplementary data.
Secondhand Tobacco Smoke Exposure and Lung Adenocarcinoma In Situ /Minimally Invasive Adenocarcinoma (AIS/MIA)
Kim, Claire H., Lee, Yuan-Chin Amy, Hung, Rayjean J., Wampfler, Jason A. , Chang, Shen-Chih, Ugolini, Donatella, Neri, Monica , Schwartz, Ann G. , Morgenstern, Hal, Zhang, Zuo‐Feng , Hung, Rayjean J. , Xie, Dong , Hung, Rayjean J., Boffetta, Paolo , Coté, Michele L. , Marchand, Loı̈c Le , Christiani, David C. , Yang, Ping , Hung, Rayjean J

Cancer Epidemiology, Biomarkers & Prevention | October 26, 2015 | Volume: 24 | Issue: 12 | Pages: 1902-1906

10.1158/1055-9965.epi-15-0436 | PMID 26503035 Get It

Abstract The aim of this study was to estimate the effect of exposure to secondhand tobacco smoke on the incidence of lung adenocarcinoma in situ/minimally invasive adenocarcinoma (AIS/MIA). Data from seven case–control studies participating in the International Lung Cancer Consortium (ILCCO) were pooled, resulting in 625 cases of AIS/MIA and 7,403 controls, of whom 170 cases and 3,035 controls were never smokers. Unconditional logistic regression was used to estimate adjusted ORs (ORadj) and 95% confidence intervals (CI), controlling for age, sex, race, smoking status (ever/never), and pack-years of smoking. Study center was included in the models as a random-effects intercept term. Ever versus never exposure to secondhand tobacco smoke was positively associated with AIS/MIA incidence in all subjects (ORadj = 1.48; 95% CI, 1.14–1.93) and in never smokers (ORadj = 1.45; 95% CI, 1.00–2.12). There was, however, appreciable heterogeneity of ORadj across studies (P = 0.01), and the pooled estimates were largely influenced by one large study (40% of all cases and 30% of all controls). These findings provide weak evidence for an effect of secondhand tobacco smoke exposure on AIS/MIA incidence. Further studies are needed to assess the impact of secondhand tobacco smoke exposure using the newly recommended classification of subtypes of lung adenocarcinoma. Cancer Epidemiol Biomarkers Prev; 24(12); 1902–6. ©2015 AACR.
Emotional Intelligence: A Novel Outcome Associated with Wellbeing and Self-Management in Chronic Obstructive Pulmonary Disease
Benzo, Roberto P. , Kirsch, Janae L. , Dulohery, Megan M., Abascal-Bolado, Beatriz

Annals of the American Thoracic Society | October 26, 2015 | Volume: 13 | Issue: 1 | Pages: 10-16

10.1513/annalsats.201508-490oc | PMID 26501370 Get It

Abstract Rationale Individuals with chronic obstructive pulmonary disease (COPD) often struggle with diminished autonomy and quality of life. Emotional factors play a crucial role in the well-being of patients with COPD; they are independently associated with critical outcomes such as dyspnea, quality of life, and health care use. Emotional intelligence is the capacity to understand and manage personal thoughts and feelings, as well as to positively influence interpersonal communication and social well-being. Emotional intelligence is a trainable skill that is extensively used in corporate business to improve well-being and performance, and it may also be significant in the self-management of emotions in patients with chronic disease. Importantly, research supports the proposition that emotional intelligence may be developed and learned at any time or any age, and training programs have been associated with increased well-being and better emotional regulation in patients with chronic disease. However, to date, no research has been done to investigate its value in patients with COPD. Objectives We aimed to investigate the association between emotional intelligence and two meaningful outcomes in COPD: quality of life and self-management abilities. Methods Participants with moderate to severe COPD completed a disease-specific quality of life tool (Chronic Respiratory Questionnaire), the Trait Emotional Intelligence Questionnaire, the Self-Management Abilities Scale, the modified Medical Research Council Dyspnea Scale, and pulmonary function tests, and also provided information about living conditions and self-reported health care use. Measurements and Main Results: A total of 310 patients with COPD (mean age, 69 ± 9 yr; 40% female; mean FEV1%, 42.4 ± 15.8) participated in the study. Emotional intelligence was significantly and independently associated with self-management abilities (P &lt; 0.0001) and all domains of quality of life assessed (dyspnea, fatigue, emotions, and mastery; P &lt; 0.0001) after adjusting for age, degree of bronchial obstruction, breathlessness, and other significant confounders. Conclusions Emotional intelligence may represent an important attribute in COPD, as it is associated with self-management abilities and all domains of quality of life, regardless of age or disease severity. Emotional intelligence can be learned and may complement existing rehabilitation efforts. Attention to it may address the current gap that exists in the treatment of emotional components of COPD responsible for decreased quality of life and increased health care use.
Interventions for smokeless tobacco use cessation
Ebbert, Jon O. , Elrashidi, Muhamad Y. , Stead, Lindsay F

Cochrane Database of Systematic Reviews | October 26, 2015 | Volume: 2025 | Issue: 7 | Pages: No page available

10.1002/14651858.cd004306.pub5 | PMID 26501380 Get It

Caveolins, Liquid-Ordered Domains, and Signal Transduction
Smart, Eric J., Graf, Gregory A. , McNiven, Mark A. , Engelman, Jeffrey A. , Scherer, Philipp E. , Sessa, William C. , Okamoto, Takashi , Lisanti, Michael P.

Molecular and Cellular Biology | October 26, 2015 | Volume: 19 | Issue: 11 | Pages: 7289-7304

10.1128/mcb.19.11.7289 | PMID 10523618 Get It